Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial

Ophthalmology

Volumn 124, Issue 2, 2017, Pages 224-234

  Jaffe, Glenn J ^a   Ciulla, Thomas A ^b   Ciardella, Antonio P ^c   Devin, Francois ^d   Dugel, Pravin U ^e   Eandi, Chiara M ^f   Masonson, Harvey ^b   Monés, Jordi ^g   Pearlman, Joel A ^h   Quaranta El Maftouhi, Maddalena ⁱ   Ricci, Federico ^j   Westby, Keith ^b   Patel, Samir C ^b  

^a DUKE UNIVERSITY EYE CENTER   (United States)

^b Ophthotech Corporation   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Centre Monticelli Paradis   (France)

^e RETINAL CONSULTANTS OF ARIZONA   (United States)

^f UNIVERSITY OF TURIN   (Italy)

^g CENTRO MÉDICO TEKNON   (Spain)

^h Retinal Consultants   (United States)

ⁱ Centre Rabelais   (France)

^j TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGPLERANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; APTAMER; E10030 APTAMER; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN A;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EYE IRRITATION; FEMALE; GLAUCOMA; HEADACHE; HUMAN; HYPERTENSION; IATROGENIC DISEASE; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA TEAR; RHINOPHARYNGITIS; SUBCONJUNCTIVAL HEMORRHAGE; TRAUMATIC CATARACT; TREATMENT DURATION; URINARY TRACT INFECTION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; APTAMERS, NUCLEOTIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PLATELET-DERIVED GROWTH FACTOR; PROSPECTIVE STUDIES; RANIBIZUMAB; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 85006007468     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2016.10.010     Document Type: Article

References (42)

1. 1 Comparison of Age-related Macular Degeneration Treatments Trials Research Group, Martin, D.F., Maguire, M.G., et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119 (2012), 1388–1398.
2. 2 Busbee, B.G., Ho, A.C., Brown, D.M., et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120 (2013), 1046–1056.
3. 3 Chakravarthy, U., Harding, S.P., Rogers, C.A., et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382 (2013), 1258–1267.
4. 4 Schmidt-Erfurth, U., Kaiser, P.K., Korobelnik, J.F., et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121 (2014), 193–201.
5. 5 Heier, J.S., Brown, D.M., Chong, V., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119 (2012), 2537–2548.
6. 6 Brown, D.M., Michels, M., Kaiser, P.K., et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116 (2009), 57–65.e5.
7. 7 Rosenfeld, P.J., Brown, D.M., Heier, J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1419–1431.
8. 8 Arevalo, J.F., Lasave, A.F., Wu, L., et al. Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the Pan-American Collaborative Retina Study Group (PACORES). Retina 36 (2016), 859–867.
9. 9 Cohen, S.Y., Mimoun, G., Oubraham, H., et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 33 (2013), 474–481.
10. 10 Holz, F.G., Tadayoni, R., Beatty, S., et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99 (2015), 220–226.
11. 11 Rakic, J.M., Leys, A., Brie, H., et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 7 (2013), 1849–1858.
12. 12 Rasmussen, A., Bloch, S.B., Fuchs, J., et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 120 (2013), 2630–2636.
13. 13 Ross, A.H., Donachie, P.H., Sallam, A., et al. Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?. Eye (Lond) 27 (2013), 56–64.
14. 14 Talks, J.S., Lotery, A.J., Ghanchi, F., et al. First-year visual acuity outcomes in the United Kingdom of providing aflibercept according to the VIEW study protocol for age-related macular degeneration. Ophthalmology 123 (2015), 337–343.
15. 15 van Asten, F., Evers-Birkenkamp, K.U., van Lith-Verhoeven, J.J., et al. A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration. Acta Ophthalmol 93 (2015), 126–133.
16. 16 Writing Committee for the U. K. Age-Related Macular Degeneration E. M. R. Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 121 (2014), 1092–1101.
17. 17 Souied, E.H., Oubraham, H., Mimoun, G., et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: The TWIN study. Retina 35 (2015), 1743–1749.
18. 18 Benjamin, L.E., Hemo, I., Keshet, E., A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125 (1998), 1591–1598.
19. 19 Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8 (2008), 592–603.
20. 20 Carmeliet, P., Jain, R.K., Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10 (2011), 417–427.
21. 21 Erber, R., Thurnher, A., Katsen, A.D., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18 (2004), 338–340.
22. 22 Helfrich, I., Schadendorf, D., Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?. Mol Oncol 5 (2011), 137–149.
23. 23 Helfrich, I., Scheffrahn, I., Bartling, S., et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 207 (2010), 491–503.
24. 24 Jo, N., Mailhos, C., Ju, M., et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168 (2006), 2036–2053.
25. 25 Hellstrom, M., Kalen, M., Lindahl, P., et al. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126 (1999), 3047–3055.
26. 26 Armulik, A., Abramsson, A., Betsholtz, C., Endothelial/pericyte interactions. Circ Res 97 (2005), 512–523.
27. 27 Andrae, J., Gallini, R., Betsholtz, C., Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22 (2008), 1276–1312.
28. 28 Hall, A.P., Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. Toxicol Pathol 34 (2006), 763–775.
29. 29 Fredriksson, L., Li, H., Eriksson, U., The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15 (2004), 197–204.
30. 30 Mitchell, T.S., Bradley, J., Robinson, G.S., et al. RGS5 expression is a quantitative measure of pericyte coverage of blood vessels. Angiogenesis 11 (2008), 141–151.
31. 31 Carmeliet, P., Jain, R.K., Molecular mechanisms and clinical applications of angiogenesis. Nature 473 (2011), 298–307.
32. 32 Jaffe, G.J., Eliott, D., Wells, J.A., et al. A phase 1 study of intravitreous E10030 in combination with ranibizumab in neovascular age-related macular degeneration. Ophthalmology 123 (2015), 78–85.
33. 33 Willoughby, A.S., Ying, G.S., Toth, C.A., et al. Subretinal hyperreflective material in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 122 (2015), 1846–1853.e5.
34. 34 Strittmatter, K., Pomeroy, H., Marneros, A.G., Targeting PDGFRBeta+ scaffold formation inhibits choroidal neovascularization. Am J Pathol 186 (2016), 1890–1899.
35. 35 Stark, K., Eckart, A., Haidari, S., et al. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and ‘instruct’ them with pattern-recognition and motility programs. Nat Immunol 14 (2013), 41–51.
36. 36 Campochiaro, P.A., Glaser, B.M., Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch Ophthalmol 103 (1985), 576–579.
37. 37 Uchihori, Y., Puro, D.G., Mitogenic and chemotactic effects of platelet-derived growth factor on human retinal glial cells. Invest Ophthalmol Vis Sci 32 (1991), 2689–2695.
38. 38 Grossniklaus, H.E., Miskala, P.H., Green, W.R., et al. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials report no. 7. Arch Ophthalmol 123 (2005), 914–921.
39. 39 Greenhalgh, S.N., Iredale, J.P., Henderson, N.C., Origins of fibrosis: pericytes take centre stage. F1000Prime Rep 5 (2013), 37–43.
40. 40 Akiyama, H., Kachi, S., Silva, R.L., et al. Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies. J Cell Physiol 207 (2006), 407–412.
41. 41 Spaide, R.F., Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 141 (2006), 149–156.
42. 42 Daniel, E., Toth, C.A., Grunwald, J.E., et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121 (2014), 656–666.